MX348932B - Polisacarido para el uso en la prevencion de la formacion y/o la reincidencia de metastasis. - Google Patents
Polisacarido para el uso en la prevencion de la formacion y/o la reincidencia de metastasis.Info
- Publication number
- MX348932B MX348932B MX2016001259A MX2016001259A MX348932B MX 348932 B MX348932 B MX 348932B MX 2016001259 A MX2016001259 A MX 2016001259A MX 2016001259 A MX2016001259 A MX 2016001259A MX 348932 B MX348932 B MX 348932B
- Authority
- MX
- Mexico
- Prior art keywords
- polysaccharide
- preventing metastasis
- metastasis formation
- relapse
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
La presente invención se refiere a un polisacárido que comprende unidades de monosacáridos opcionalmente sustituidas unidas a través de uniones alfa-glucosídicas para el uso en la prevención de la formación y/o la reincidencia de metástasis por medio de la administración a una cavidad del cuerpo de un sujeto que padece de cáncer. La presente invención se refiere además a un método para prevenir la formación de metástasis en un sujeto que padece de cáncer, que comprende administrar dicha composición a una cavidad del cuerpo de dicho sujeto y prevenir, de ese modo, la formación de metástasis en dicho sujeto. La presente invención también se refiere a una composición y a un kit que comprende un polisacárido y un medio farmacéuticamente aceptable de solubilización de este y a un dispositivo que comprende un polisacárido y medios para la administración de este.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13178566.9A EP2832360A1 (en) | 2013-07-30 | 2013-07-30 | Polysaccharide for use in preventing metastasis formation and/or relapse |
| PCT/EP2014/065990 WO2015014730A1 (en) | 2013-07-30 | 2014-07-25 | Polysaccharide for use in preventing metastasis formation and/or relapse |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016001259A MX2016001259A (es) | 2016-07-21 |
| MX348932B true MX348932B (es) | 2017-07-04 |
Family
ID=48900829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016001259A MX348932B (es) | 2013-07-30 | 2014-07-25 | Polisacarido para el uso en la prevencion de la formacion y/o la reincidencia de metastasis. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20160175340A1 (es) |
| EP (3) | EP2832360A1 (es) |
| KR (2) | KR20190092615A (es) |
| CN (1) | CN105555280A (es) |
| AU (1) | AU2014298637B2 (es) |
| CA (1) | CA2918180A1 (es) |
| DK (1) | DK3027196T3 (es) |
| ES (1) | ES2628207T3 (es) |
| HK (2) | HK1206643A1 (es) |
| HR (1) | HRP20170877T1 (es) |
| HU (1) | HUE032564T2 (es) |
| LT (1) | LT3027196T (es) |
| MX (1) | MX348932B (es) |
| PL (1) | PL3027196T3 (es) |
| PT (1) | PT3027196T (es) |
| RS (1) | RS56062B1 (es) |
| SI (1) | SI3027196T1 (es) |
| WO (1) | WO2015014730A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111647096B (zh) * | 2020-05-20 | 2021-04-06 | 昆明理工大学 | 一种中性玛咖多糖及其提取方法与应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5616765B2 (es) | 1975-02-05 | 1981-04-18 | ||
| DE4023788A1 (de) | 1990-07-26 | 1992-01-30 | Schumann Klaus | Verwendung einer waessrigen loesung einer poly-(o-hydroxyalkyl)-staerke |
| US5807833A (en) | 1995-06-07 | 1998-09-15 | University Of Southern California | Hydroxyethyl starch and use thereof as an absorbable mechanical barrier and intracavity carrier device |
| US6207654B1 (en) | 1996-05-03 | 2001-03-27 | Bashir Zikria | Capillary membrane stabilization and reduction of inflammation during the course of chemotherapy or antiviral treatment through the use of biodegradable macromolecules and interleukin-2 |
| ATE462437T1 (de) | 2002-09-04 | 2010-04-15 | Biopolymer Engineering Inc | Krebstherapie mit ganzen glukan-teilchen und antikörpern |
| EP1984004A4 (en) | 2006-01-17 | 2010-03-03 | Sloan Kettering Inst Cancer | THE THERAPY REINFORCING GLUCAN |
| EP2398482B1 (en) * | 2009-02-17 | 2017-04-19 | NovelMed Therapeutics, Inc. | Methods and compositions for inhibiting cellular proliferation and surgical adhesion |
| EP2590680A1 (en) | 2010-07-09 | 2013-05-15 | Fresenius Kabi Deutschland GmbH | Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
| SI2809327T1 (sl) * | 2012-01-30 | 2018-12-31 | Fresenius Kabi Deutschland Gmbh | Hidroksialkil škrob v kombinaciji s citostatiki za zdravljenje rakov z zmanjševanjem stopenj rasti tumorja |
-
2013
- 2013-07-30 EP EP13178566.9A patent/EP2832360A1/en not_active Withdrawn
-
2014
- 2014-07-25 LT LTEP14745106.6T patent/LT3027196T/lt unknown
- 2014-07-25 ES ES14745106.6T patent/ES2628207T3/es active Active
- 2014-07-25 CA CA2918180A patent/CA2918180A1/en not_active Abandoned
- 2014-07-25 PT PT147451066T patent/PT3027196T/pt unknown
- 2014-07-25 WO PCT/EP2014/065990 patent/WO2015014730A1/en active Application Filing
- 2014-07-25 HU HUE14745106A patent/HUE032564T2/en unknown
- 2014-07-25 KR KR1020197022364A patent/KR20190092615A/ko not_active Application Discontinuation
- 2014-07-25 EP EP17160891.2A patent/EP3202408A3/en not_active Withdrawn
- 2014-07-25 KR KR1020167005343A patent/KR20160044493A/ko active Application Filing
- 2014-07-25 MX MX2016001259A patent/MX348932B/es active IP Right Grant
- 2014-07-25 PL PL14745106T patent/PL3027196T3/pl unknown
- 2014-07-25 SI SI201430248A patent/SI3027196T1/sl unknown
- 2014-07-25 RS RS20170591A patent/RS56062B1/sr unknown
- 2014-07-25 DK DK14745106.6T patent/DK3027196T3/en active
- 2014-07-25 EP EP14745106.6A patent/EP3027196B1/en active Active
- 2014-07-25 CN CN201480043108.7A patent/CN105555280A/zh active Pending
- 2014-07-25 US US14/909,300 patent/US20160175340A1/en not_active Abandoned
- 2014-07-25 AU AU2014298637A patent/AU2014298637B2/en not_active Ceased
-
2015
- 2015-08-03 HK HK15107429.9A patent/HK1206643A1/xx unknown
-
2016
- 2016-12-06 HK HK16113882A patent/HK1225615B/zh not_active IP Right Cessation
-
2017
- 2017-06-08 HR HRP20170877TT patent/HRP20170877T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160044493A (ko) | 2016-04-25 |
| EP3027196A1 (en) | 2016-06-08 |
| EP2832360A1 (en) | 2015-02-04 |
| HUE032564T2 (en) | 2017-09-28 |
| PL3027196T3 (pl) | 2017-09-29 |
| CA2918180A1 (en) | 2015-02-05 |
| WO2015014730A1 (en) | 2015-02-05 |
| MX2016001259A (es) | 2016-07-21 |
| AU2014298637A1 (en) | 2016-02-25 |
| KR20190092615A (ko) | 2019-08-07 |
| ES2628207T3 (es) | 2017-08-02 |
| DK3027196T3 (en) | 2017-06-26 |
| EP3202408A3 (en) | 2017-09-20 |
| WO2015014730A4 (en) | 2015-04-09 |
| RS56062B1 (sr) | 2017-10-31 |
| HRP20170877T1 (hr) | 2017-09-22 |
| PT3027196T (pt) | 2017-06-26 |
| SI3027196T1 (sl) | 2017-07-31 |
| EP3027196B1 (en) | 2017-03-15 |
| LT3027196T (lt) | 2017-06-26 |
| AU2014298637B2 (en) | 2019-03-21 |
| HK1225615B (zh) | 2017-09-15 |
| US20160175340A1 (en) | 2016-06-23 |
| HK1206643A1 (en) | 2016-01-15 |
| CN105555280A (zh) | 2016-05-04 |
| EP3202408A2 (en) | 2017-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2015000396A1 (en) | Antibody drug conjugates | |
| CL2016000468A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso. | |
| PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
| MX2016004678A (es) | Composiciones para el tratamiento del cancer. | |
| MX2015009105A (es) | Composiciones en solucion solida y su uso en inflamacion cronica. | |
| BR112015030514A2 (pt) | Composições e métodos para conjugação de anticorpos ativáveis | |
| IN2014DN09098A (es) | ||
| MX366317B (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
| MX2013008851A (es) | Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias. | |
| MX2015014431A (es) | Monoterapia con glucopiranosil lipido a para usarse en el tratamieto del cancer. | |
| UY36075A (es) | Derivados de tubulisina | |
| MX2020012924A (es) | Terapias combinadas de coenzima q10 para el tratamiento de cancer. | |
| MX2015015518A (es) | Metodos y composiciones para el tratamiento del cancer. | |
| MX2012000396A (es) | Metodos y composiciones para uso en tartamientos celulares. | |
| MX2015009045A (es) | Composiciones y metodos para tratar el dolor severo. | |
| TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
| WO2014160281A3 (en) | Method of enhancing delivery of therapeutic compounds to the eye | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| MX2016015568A (es) | Derivados de nucleosidos para el tratamiento del cancer. | |
| PH12015502564A1 (en) | Pyridone derivatives for the treatment of viral infections and further diseases | |
| MX2013010947A (es) | Complejos de galio, composiciones farmacéuticas y métodos de uso. | |
| MX370957B (es) | Compuesto de la familia de la avermectina o de la familia de la milbemicina para el tratamiento y/o la prevención de la dermatitis atópica. | |
| MX2016001259A (es) | Polisacarido para el uso en la prevencion de la formacion y/o la reincidencia de metastasis. | |
| GB2527233A (en) | Composition comprising hydrocortisone | |
| PH12017501979A1 (en) | Pharmaceutical compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |